Regulus Therapeutics reported $0 in Sales Revenues for its fourth fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Sales Change
Alnylam Pharmaceuticals ALNY:US USD 264.31M 39.49M
Astrazeneca AZN:US USD 10.98B 211M
AstraZeneca AZN:LN USD 10.98B 211M
Biogen BIIB:US USD 2.51B 80.6M
Celldex Therapeutics CLDX:US USD 407K 244K
Gilead Sciences GILD:US USD 7.04B 782M
GlaxoSmithKline GSK:LN GBP 782.9B 90B
Intercept Pharmaceuticals ICPT:US USD 77.59M 5.83M
Intrexon XON:US USD 16.72M 13.81M
Lexicon Pharmaceuticals LXRX:US USD 39K 4K
Ligand Pharmaceuticals LGND:US USD 62.51M 5.09M
Merk MRK:US USD 14.96B 366M
Sangamo Biosciences SGMO:US USD 26.46M 2.92M
Takeda 4502:JP JPY 1T 29.84B
YTE INCY:US USD 823.3M 88.09M